Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oxymetazoline hydrochloride eye drops for acquired blepharoptosis in China
CTR20243263Phase 3Active
- Sponsor
- Santen Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxymetazoline in acquired blepharoptosis, sponsored by Santen Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on CTR20243263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243263.